Patients should point out the need to adhere to their dietary recommendations.
Diet and exercise are an important component of the program to reduce body weight. It is recommended to begin the diet program and physical exercises before the beginning of therapy with the drug. During the use of the drug, the patient should receive a moderately hypocaloric diet with a balanced nutrient content, in which approximately 30% is fat.Daily intake of fat should be distributed among the three main meals. It is recommended that food be rich in fruits and vegetables. The program of diet and exercise should be continued after the drug has been discontinued.
The use of Orlixen 60 should be discontinued if, after 12 weeks of therapy, body weight decreased by less than 5% compared to the initial body weight.
The likelihood of side effects from the gastrointestinal tract is higher if a single meal or diet as a whole is characterized by a high fat content. A diet low in fat reduces the likelihood of developing adverse events from the gastrointestinal tract.
Patients with kidney disease should consult with a physician, since possibly the development of hyperoxaluria and nephropathy.
Since weight loss may be accompanied by an improvement in metabolic control in patients with diabetes mellitus, those who receive hypoglycemic drugs should consult their physician before starting to use Orlixen 60 and, if necessary, adjust the dose hypoglycemic agents.
Decreased body weight may be accompanied by an improvement in blood pressure and a decrease in cholesterol concentration. Patients taking medications for hypertension or hypercholesterolemia should be consulted with a doctor when using Orlixen 60 and, if necessary, correct the dose of these drugs.
When orlistat was used, cases of rectal bleeding were observed. If severe and / or persistent bleeding symptoms occur, additional testing is necessary.
It is recommended to use an additional method of contraception to prevent possible ineffectiveness of oral contraceptives in the event of diarrhea.
If symptoms such as weakness, fatigue, fever, jaundice and darkening of the urine occur, you should consult your doctor to rule out liver damage.
When Orlistat was used, rare cases of development of hypothyroidism and / or violation of its control were noted. The mechanism of development of this phenomenon is unknown, but it can be caused by a decrease in absorption of iodized salt and / or levothyroxine sodium.
Orlistat has the potential to reduce the absorption of antiretroviral drugs to treat HIV and to reduce the effectiveness of antiretroviral therapy. Before starting orlistat therapy, you should carefully evaluate the benefit / risk ratio in such patients.
When using orlistat, the development of oxalate nephropathy is possible, which can sometimes lead to the development of renal failure. An increased risk is noted in patients with chronic renal failure and / or dehydration.